The research desk

Someone should read the paperwork.

Every new trial, regulator warning and shortage notice about Ozempic and the rest of the GLP-1 class — summarised in our own words, with the source attached so you can check us. No hype, no brand cheerleading, no "miracles".

Sourced, always. One click to the paper, alert or release behind every claim.

Our words, their facts. We summarise and link. We never republish an article, abstract or photo.

Evidence labelled. A mouse study never gets dressed up as a trial.

Not medical advice. We explain the research; your prescriber explains you.

Latest briefs

ObservationalOther research13 November 2026

Genetic variations may influence weight-loss response to semaglutide

New research suggests that specific rare genetic variants in the GLP-1 receptor gene could significantly reduce the effectiveness of semaglutide for weight management.

Source: Nature Metabolism1 min read
Regulator alertSafety alerts13 November 2026

FDA mandates eye-health warnings for all GLP-1 medications

Regulators have ordered a class-wide label update following a review of potential links between these drugs and a rare form of optic nerve damage.

Source: Medscape1 min read
Regulator alertSafety alerts12 November 2026

US regulators order a vision-loss warning onto GLP-1 labels

The FDA wants a rare eye condition named on the labels of Ozempic, Wegovy and the rest of the class. Here is what the alert says — and what it can't.

Source: BBC News1 min read
AnalysisSafety alerts12 November 2026

Pancreatitis warnings: what the evidence on GLP-1 drugs can and can't show

Britain and Brazil have told doctors and patients to watch for an inflamed pancreas in people using GLP-1 jabs. We looked at how far the evidence behind that warning actually stretches.

Source: Nature1 min read
Lab & animal studyOzempic & semaglutide12 November 2026

Ozempic may work by waking the brain's hunger neurons, not silencing them

A Yale study in mice found semaglutide needs the very neurons everyone assumed it switched off. It rewrites the textbook story of how these drugs keep weight off.

Source: Yale News (PNAS study)1 min read
Real-world dataThe whole class12 November 2026

A manufacturer's study says staying on Ozempic beat switching to Mounjaro. Read the asterisks.

Novo Nordisk's own real-world analysis reported fewer heart attacks, strokes and deaths in people who increased their Ozempic dose instead of switching drugs. It is interesting. It is also marketing-adjacent.

Source: Novo Nordisk press release (PR Newswire)1 min read

The desk summarises published research and official alerts. It is not medical advice, and it is never a reason to start, stop or change a medicine on your own. If something feels wrong in your body, talk to a clinician — or call 111.